- Home
- PBM vs BPTH Comparison
PBM vs BPTH Comparison
Compare PBM & BPTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBM
- BPTH
- Stock Information
- Founded
- PBM 1994
- BPTH 2007
- Country
- PBM Canada
- BPTH United States
- Employees
- PBM N/A
- BPTH N/A
- Industry
- PBM
- BPTH Biotechnology: Pharmaceutical Preparations
- Sector
- PBM
- BPTH Health Care
- Exchange
- PBM NYSE
- BPTH Nasdaq
- Market Cap
- PBM 2.8M
- BPTH 2.8M
- IPO Year
- PBM N/A
- BPTH N/A
- Fundamental
- Price
- PBM $1.53
- BPTH $0.67
- Analyst Decision
- PBM
- BPTH Strong Buy
- Analyst Count
- PBM 0
- BPTH 2
- Target Price
- PBM N/A
- BPTH $30.00
- AVG Volume (30 Days)
- PBM 2.2M
- BPTH 107.0K
- Earning Date
- PBM 02-02-2025
- BPTH 11-15-2024
- Dividend Yield
- PBM N/A
- BPTH N/A
- EPS Growth
- PBM N/A
- BPTH N/A
- EPS
- PBM N/A
- BPTH N/A
- Revenue
- PBM N/A
- BPTH N/A
- Revenue This Year
- PBM N/A
- BPTH N/A
- Revenue Next Year
- PBM N/A
- BPTH N/A
- P/E Ratio
- PBM N/A
- BPTH N/A
- Revenue Growth
- PBM N/A
- BPTH N/A
- 52 Week Low
- PBM $1.51
- BPTH $0.59
- 52 Week High
- PBM $945.15
- BPTH $12.00
- Technical
- Relative Strength Index (RSI)
- PBM 20.19
- BPTH 39.07
- Support Level
- PBM $1.85
- BPTH $0.64
- Resistance Level
- PBM $2.11
- BPTH $0.90
- Average True Range (ATR)
- PBM 0.55
- BPTH 0.10
- MACD
- PBM 0.07
- BPTH 0.01
- Stochastic Oscillator
- PBM 0.80
- BPTH 25.48
About PBM PSYENCE BIOMEDICAL LTD
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.